IMM.L
ImmuPharma Plc
Latest RNS
Powered by Vox Markets
- Immupharma PLC - Repayment of Convertible Security
- Immupharma PLC - Update on submission to the FDA
- Immupharma PLC - Conversion of Convertible Security
- Immupharma PLC - Conversion of Convertible Security
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Director/PDMR Shareholding / TR -1
- Immupharma PLC - Placing - update; related party transaction)
- Immupharma PLC - Conversion of Convertible Security
- Immupharma PLC - Placing to raise £6.5 million
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - FDA submission for Special Protocol Assessment
- Immupharma PLC - 2020 AGM – ALL RESOLUTIONS PASSED
- Immupharma PLC - Total Share Capital Notification
- Immupharma PLC - TR-1 Notification of major holdings
- Immupharma PLC - STRAT. INVTS FROM 2 SPECIALIST US H'CARE INVESTORS
- Immupharma PLC - Change of Registered Office Address
- Immupharma PLC - Notification of Change of AGM Venue
- Immupharma PLC - Notice of AGM and posting of Report & Accounts
- Immupharma PLC - TR-1: Notification of major holdings
- Immupharma PLC - Efforts in fight vs Covid-19 with Lupuzor; Ureka
- Immupharma PLC - Audited Report & Accounts published on website
- Immupharma PLC - FINAL RESULTS FOR THE 12M ENDED 31/12/19
- Immupharma PLC - IMM live on Investor Meet Company platform 7 April
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - £1.5m Subscrip'n to fund R&D pipeline- replacement
- Immupharma PLC - £1.5m Subscription to fund R&D pipeline expansion
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Incanthera plc – Admission to trading on NEX
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Incanthera announces Rule 23 Notice re NEX listing
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Update on the Avion Agreement
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Admission today to trading on Euronext Growth
- Immupharma PLC - Publication of Information Note (Euronext Growth)
- Immupharma PLC - Dual Listing on Euronext Growth Brussels
- Immupharma PLC - Share Price Volatility
- Immupharma PLC - IMMUPHARMA TO PRESENT AT BIOTECH SHOWCASET 2020
- Immupharma PLC - TR-1: notification of major holdings
- Immupharma PLC - Licence Agreement for Lupuzor with Avion in US
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Interim Results Announcement
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - TR-1: notification of major holdings
- Immupharma PLC - TR-1: notification of major holdings
- Immupharma PLC - TR-1: notification of major holdings
- Immupharma PLC - Update on Lupuzor
- Immupharma PLC - 2019 Annual General Meeting
- Immupharma PLC - Subscription to raise £2.66 million
- Immupharma PLC - Notice of AGM and posting of Report & Accounts
- Immupharma PLC - FINAL RESULTS
- Immupharma PLC - Corporate Update - Replacement
- Immupharma PLC - Corporate Update - Replacement
- Immupharma PLC - Corporate Update
- Immupharma PLC - Update on Nucant Cancer Programme
- Immupharma PLC - Corporate Update
- Immupharma PLC - Technology review published-Nature Communications
- Immupharma PLC - Clinical Development Collaboration with Incanthera
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Appointment of Nominated Adviser
- Immupharma PLC - Update on Corporate Activities
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Nominated Adviser Status
- Immupharma PLC - Interim Results
- Immupharma PLC - Appointment of Joint Brokers
- Immupharma PLC - Corporate Update
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Result of AGM
- Immupharma PLC - Results of CIDP Pre-Clinical Data
- Immupharma PLC - Notice of AGM & Posting of Annual Report
- Immupharma PLC - Final Results
- Immupharma PLC - Update on Pivotal Phase III Trial of Lupuzor
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Topline results of Lupuzor Pivotal Phase III Trial
- Immupharma PLC - Appointment of Joint Broker
- Immupharma PLC - Lupuzor Pivotal Phase III Study Update
- Immupharma PLC - AIM Notice (17)
- Immupharma PLC - Grant of Options
- Immupharma PLC - Last patient completes dosing in LupuzorT Trial
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Grant of Options
- Immupharma PLC - Update on LupuzorT Pivotal Phase III Study
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Completion of Lanstead Sharing Agreement
- Immupharma PLC - Interim Results
- Immupharma PLC - Preparation of Lupuzor'sT Regulatory Submissions
- Immupharma PLC - Update on LupuzorT Pivotal Phase III Study
- Immupharma PLC - Notification of Interim Results
- Immupharma PLC - AIM Rule 17 Notice
- Immupharma PLC - Grant of Options
- Immupharma PLC - Result of AGM
- Immupharma PLC - Update on LupuzorT Pivotal Phase III Study
- Immupharma PLC - Annual Report & Notice of AGM
- Immupharma PLC - Final Results
- Immupharma PLC - Notification of Full Year Results
- Immupharma PLC - Update on Lupuzor Phase III Study
- Immupharma PLC - New Employee Share Option Plan & Grant of Options
- Immupharma PLC - New Employee Share Option Plan & Grant of Options
- Immupharma PLC - ImmuPharma to present at Master Investor Show
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - £4.1 Million Fund Raise via Accelerated Bookbuild
- Immupharma PLC - Accelerated Bookbuild for the Issue of Equity
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Update on Lupuzor Phase III Study
- Immupharma PLC - Change of Adviser
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Update on Lupuzor Pivotal Phase III Study
- Immupharma PLC - Update on Cancer Compound IPP-204106 'Nucant'
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Close of Accelerated Bookbuild
- Immupharma PLC - Proposed Accelerated Bookbuild for Vendor Placing
- Immupharma PLC - Half-year Report
- Immupharma PLC - UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
- Immupharma PLC - UPDATE ON LUPUZOR'S PIVOTAL PHASE III STUDY
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Second Price Monitoring Extn
- Immupharma PLC - Price Monitoring Extension
- Immupharma PLC - Appointment of Joint Broker
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Symposium with Lupuzors Inventor Prof. S Muller
- Immupharma PLC - European Patients Commence Dosing in Lupuzor
- Immupharma PLC - Director/PDMR Shareholding
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Result of AGM
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Annual Financial Report & Notice of AGM
- Immupharma PLC - Final Results
- Immupharma PLC - Notice of Results
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - First European Site Opens - Patient Recruitment
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - EIS and VCT Qualifying Status and Issue of Equity
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Issue of Equity
- Immupharma PLC - Result of GM
- Immupharma PLC - US PATIENTS COMMENCE DOSING IN PHASE III STUDY
- Immupharma PLC - Placing and Subscription Raises £8.3 million
- Immupharma PLC - Proposed Placing and Subscription
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - ImmuPharma & Simbec-Orion - Investigators Meeting
- Immupharma PLC - Update on the progress of Lupuzor
- Immupharma PLC - Holding(s) in Company
- Immupharma PLC - Lupuzor Phase III Pivotal Trial Update
- Immupharma PLC - Lupuzor Phase III Pivotal Trial Update
- Immupharma PLC - Directorate Change
- Immupharma PLC - Directorate Change
- Immupharma PLC - Interim Results